Key result
BrainQuant fails to distinguish cerebral ALD but correlates with myelopathy severity.
Why the study?
The authors assessed whether quantitative MRI parameters from an automated tool (BrainQuant) could differentiate CALD from non-CALD and reflect myelopathy severity in X-linked adrenoleukodystrophy.
Does an automated DTI-based quantitative MRI tool differentiate cerebral ALD from non-cerebral ALD and track myelopathy severity in adult males with X-linked adrenoleukodystrophy?
Cohort (n=62)
Does an automated DTI-based quantitative MRI tool differentiate cerebral ALD from non-cerebral ALD and track myelopathy severity in adult males with X-linked adrenoleukodystrophy?
p-value: p=0.748
An automated DTI-based quantitative MRI tool (BrainQuant) effectively tracks myelopathy severity and progression in X-linked adrenoleukodystrophy, with global radial diffusivity serving as a promising biomarker.
DTI metrics may track myelopathy severity in advanced ALD; leaves open validation as a progression biomarker.
X-linked adrenoleukodystrophy (X-ALD) is caused by ABCD1 pathogenic variants, leading to accumulation of very long-chain fatty acids (VLCFAs). Phenotypes include cerebral ALD (CALD) and adrenomyeloneuropathy (AMN). We assessed if quantitative MRI (qMRI) parameters from an automated tool (BrainQuant) could differentiate CALD from non-CALD and reflects myelopathy severity. Adult males from a prospective study (2015-2024) underwent annual neurological exams and brain MRI. Exclusion criteria were: fewer than two MRIs, non-ALD lesions, or prior transplantation. BrainQuant processed diffusion tensor imaging (DTI) to yield global metrics: fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Patients were stratified by Loes score (0 vs. > 0) and expanded disability status scale (EDSS ≤ 2 vs. > 2). Longitudinal changes were modeled. Correlations with EDSS, severity score for progressive myelopathy (SSPROM), and 6-min walk test (6-MWT) were analyzed. The cohort included 62 patients (median age 36.5); 15 had CALD. Global DTI metrics did not differ significantly between CALD and non-CALD. A trend for higher radial diffusivity (RD) in the splenium (p = 0.037) was seen, but results were not significant after Bonferroni correction for multiple comparisons (p = 0.748). Patients with EDSS > 2 showed significantly worse global DTI values (p < 0.05), correlating with clinical scores (r = 0.40-0.69). Longitudinally, RD-global increased significantly (p < 0.001) at similar rates across EDSS groups. BrainQuant qMRI did not distinguish CALD and non-CALD but effectively tracked myelopathy. Radial diffusivity (RD)-global is a promising biomarker for monitoring X-ALD progression.
No takes yet. Share an insight, caveat, or question.
Kabak et al. (2025) conducted a cohort in X-linked adrenoleukodystrophy (X-ALD) (n=62). BrainQuant automated quantitative MRI (DTI metrics) vs. Non-CALD or EDSS ≤ 2 was evaluated on Differentiation of CALD from non-CALD using global DTI metrics (p=0.748). BrainQuant automated quantitative MRI did not distinguish cerebral from non-cerebral ALD (p=0.748), but global radial diffusivity significantly correlated with myelopathy severity (r=0.40-0.69).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: